The estimated Net Worth of Kinney Horn is at least $95.2 Tausend dollars as of 10 March 2022. Mr Horn owns over 5,253 units of Olema Pharmaceuticals stock worth over $95,154 and over the last 4 years he sold OLMA stock worth over $0.
Mr has made over 11 trades of the Olema Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 5,253 units of OLMA stock worth $10,821 on 10 March 2022.
The largest trade he's ever made was exercising 57,763 units of Olema Pharmaceuticals stock on 18 May 2021 worth over $118,992. On average, Mr trades about 7,805 units every 17 days since 2020. As of 10 March 2022 he still owns at least 7,711 units of Olema Pharmaceuticals stock.
You can see the complete history of Mr Horn stock trades at the bottom of the page.
Kinney Horn is the Chief Bus. Officer at Olema Pharmaceuticals.
Mr Horn is 47, he's been the Chief Bus. Officer of Olema Pharmaceuticals since . There are 7 older and no younger executives at Olema Pharmaceuticals. The oldest executive at Olema Pharmaceuticals, Inc. is Dr. Peter J. Kushner Ph.D., 82, who is the Chief Scientific Officer.
Kinney's mailing address filed with the SEC is C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011.
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham und Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals executives and other stock owners filed with the SEC include: